- Global Operation
- Contract Manufacturing
Rifaximin is a non-aminoglycoside, semi-synthetic, non-systemic antibiotic derived from rifamycin. Rifaximin acts by binding to the beta-subunit of bacterial DNA-dependent RNA polymerase resulting in inhibition of bacterial RNA synthesis.
Rifaximin is a semisynthetic, rifamycin-based non-systemic antibiotic. Very little of the drug will pass the gastrointestinal wall into the circulation as is common for other types of orally administered antibiotics. Rifaximin inhibits bacterial RNA synthesis by its action on the beta-subunit of the
DNA-dependent RNA polymerase. It shows the same
broad-spectrum activity as rifamycin which exerts bactericidal action against many species of Gram-positive and Gram-negative, aerobic and anaerobic bacteria.
Acute Infectious Diarrhea including Travelers' Diarrhea, Diarrhea predominant Irritable Bowel Syndrome (IBS-D)
Hepatic Encephalopathy (HE).
Ibida® Tablet 200 mg: Each box contains 2x10's tablets in Alu-Alu blister Pack.
Ibida® Tablet 550 mg: Each box contains 2x10's tablets in Alu-Alu blister Pack.